Pending Challenges in early-phase Clinical Studies of Immunotherapy, Gonzalo J. Rubio, Executive Medical Director, Oncology.
- Paradigms in endpoint selection
- Risks of continuing using an extrapolated modeling
- Seamless study designs: pros and cons
- Redundancy and inefficiency
- Combination studies
- Future directions
Dr Gonzalo J. Rubio has more than 25 years expertise in Oncology Clinical Drug Development, from early phase studies up to regulatory registration, pharmacovigilance and post-marketing research, both as Investigator and Medical Monitor